全球 miRNA 定序與檢測市場

預計到 2030 年全球 miRNA 定序和檢測市場規模將達到 7.631 億美元

2024 年全球 miRNA 定序和檢測市場規模估計為 3.79 億美元，預計到 2030 年將達到 7.631 億美元，2024-2030 年分析期內的複合年成長率為 12.4%。報告分析的細分市場之一，miRNA 定序和檢測產品，預計在分析期結束時將達到 11.9% 的複合年成長率，達到 6.035 億美元。在分析期內，miRNA 定序和檢測服務部分預計將以 14.3% 的複合年成長率成長。

美國市場規模估計為 1.033 億美元；中國市場預期複合年成長率為 16.5%

預計 2024 年美國miRNA 定序和檢測市場價值將達到 1.033 億美元。中國是世界第二大經濟體，預計到 2030 年市場規模將達到 1.595 億美元，2024-2030 年分析期間的複合年成長率為 16.5%。其他值得注意的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為 9.1% 和 11.0%。在歐洲，德國的複合年成長率預計為 9.8%。

全球 miRNA 定序和檢測市場 - 主要趨勢和促進因素摘要

miRNA定序為何在生物醫學研究領域引起前所未有的關注？

微型RNA（miRNA）定序已成為了解基因調控及其在各種疾病中的影響的重要工具。隨著癌症、神經退化性疾病和心血管疾病等複雜疾病的增加，研究人員擴大轉向 miRNA 分析來識別生物標記和治療標靶。 miRNA 控制基因表現和參與細胞過程的能力使其在精準醫療中具有不可估量的價值。基因組學的投資不斷增加以及次世代定序儀(NGS) 技術的進步進一步刺激了 miRNA 定序的採用。此外，資助生命科學研究的公共和私人舉措正在加速尖端 miRNA 檢測技術的發展。個人化醫療日益成長的興趣也促進了需求，因為 miRNA 定序提供了個人化治療所需的精確度和特異性。

技術進步如何徹底改變 miRNA 檢測市場？

miRNA 檢測市場正在經歷技術變革時期，推動力來自定定序平台和生物資訊學工具的創新。單細胞 RNA 定序等先進的定序技術使研究人員能夠更深入地了解 miRNA 表現及其在疾病途徑中的作用。此外，人工智慧和機器學習在資料分析中的整合簡化了複雜 miRNA資料集的解釋，使研究人員和臨床醫生更容易獲得該技術。檢測試劑套件的創新，包括更高的敏感度和特異性，使得 miRNA 檢測更加可靠。此外，可以同時分析多個 miRNA 的多重檢測的發展大大降低了大規模研究所需的成本和時間。這些進展不僅提高了 miRNA 分析的整體效率，而且拓寬了其在診斷、藥物發現和治療開發中的潛在應用。

醫療保健應用在市場擴張中將扮演什麼角色？

miRNA定序在醫療保健領域的應用是市場擴張的主要驅動力。例如，在腫瘤學領域，miRNA 分析被用於開發可早期發現癌症、預測患者結果和監測病情進展的診斷測試。同樣，在神經病學領域，miRNA 正在被研究作為阿茲海默症、帕金森氏症和其他神經退化性疾病的生物標記。除了診斷之外，miRNA 檢測在治療領域也引起了人們的興趣，許多臨床試驗正在探索其在標靶治療中的應用。 miRNA定序在產前篩檢、感染疾病診斷和免疫反應監測中的整合進一步證明了其多功能性。慢性病發病率的不斷上升、全球對早期檢測和精準醫療的關注預計將維持醫療保健領域對 miRNA 測序和檢測的需求。

是什麼推動了 miRNA 定序和檢測市場的成長？

miRNA 定序和檢測市場的成長受到多種因素的推動，這些因素凸顯了其在生物醫學研究和醫療保健進步中的關鍵作用。癌症和慢性病發病率的上升大大增加了基於 miRNA 的診斷和治療的需求。 NGS 技術的進步使得 miRNA 定序更加準確、經濟高效且廣泛可用，進一步支持了市場採用。人們對個人化醫療的日益關注以及 miRNA 分析在藥物研發過程中的日益整合也是主要促成因素。此外，miRNA 在非侵入性液態切片中的應用不斷擴大，以及它們在闡明疾病機制中的作用，增加了 miRNA 在現代醫學中的相關性。這些綜合促進因素正在推動市場格局實現強勁成長，並重塑基因組研究和臨床格局。

部分

產品與服務（miRNA 定序與檢測產品、miRNA 定序與檢測服務）、技術（合成定序、寡核苷酸連接與檢測定序 (SOLiD)、奈米孔定序、桑格定序、單分子即時 (SMRT) 定序）、應用（癌症、多聚谷氨醯胺疾病、自體免疫疾病、思覺失調症、其他學術技術用途）

受訪公司範例（27家值得關注的公司）

• Abcam Plc
• HTG Molecular Diagnostics, Inc.
• Illumina, Inc.
• Lexogen
• Meridian Bioscience, Inc.
• New England Biolabs, Inc.
• Norgen Biotek Corp.
• QIAGEN NV
• System Biosciences, LLC
• Takara Bio Inc

目錄

第1章調查方法

第 2 章執行摘要

• 市場概況
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章 市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲國家
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

2025 年非洲 miRNA定序和檢測市場存在 - 強大 / 活躍 / 小眾 / 瑣碎 - 主要競爭對手（E）

第4章 競賽

Global miRNA Sequencing and Assays Market to Reach US$763.1 Million by 2030

The global market for miRNA Sequencing and Assays estimated at US$379.0 Million in the year 2024, is expected to reach US$763.1 Million by 2030, growing at a CAGR of 12.4% over the analysis period 2024-2030. miRNA Sequencing & Assay Products, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$603.5 Million by the end of the analysis period. Growth in the miRNA Sequencing & Assay Services segment is estimated at 14.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$103.3 Million While China is Forecast to Grow at 16.5% CAGR

The miRNA Sequencing and Assays market in the U.S. is estimated at US$103.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$159.5 Million by the year 2030 trailing a CAGR of 16.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR.

Global miRNA Sequencing and Assays Market - Key Trends & Drivers Summarized

Why Is miRNA Sequencing Gaining Unprecedented Attention in Biomedical Research?

MicroRNA (miRNA) sequencing has emerged as a critical tool in understanding gene regulation and its implications in various diseases. With the rise in complex diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions, researchers are increasingly turning to miRNA profiling to identify biomarkers and therapeutic targets. The ability of miRNAs to regulate gene expression and play a role in cellular processes makes them invaluable in precision medicine. The growing investment in genomics and advancements in next-generation sequencing (NGS) technologies have further fueled the adoption of miRNA sequencing. Moreover, public and private initiatives to fund life sciences research are accelerating the development of cutting-edge miRNA assay technologies. The increasing interest in personalized medicine is also contributing to the demand, as miRNA sequencing provides the precision and specificity required to tailor treatments.

How Are Technological Advancements Revolutionizing the miRNA Assays Market?

The miRNA assays market is undergoing a technological transformation, driven by innovations in sequencing platforms and bioinformatics tools. Advanced sequencing technologies, such as single-cell RNA sequencing, are enabling researchers to obtain more detailed insights into miRNA expression and its role in disease pathways. Additionally, the integration of artificial intelligence and machine learning in data analysis has simplified the interpretation of complex miRNA datasets, making the technology more accessible to researchers and clinicians. Innovations in assay kits, including higher sensitivity and specificity, have enhanced the reliability of miRNA detection. Furthermore, the development of multiplexed assays that can simultaneously analyze multiple miRNAs has significantly reduced the cost and time associated with large-scale studies. These advancements not only improve the overall efficiency of miRNA analysis but also broaden its applicability in diagnostics, drug discovery, and therapeutic development.

What Role Do Healthcare Applications Play in Expanding the Market?

The application of miRNA sequencing in healthcare is a major driver of its market expansion. In oncology, for instance, miRNA profiling is being used to develop diagnostic tests that can detect cancer at an early stage, predict patient outcomes, and monitor disease progression. Similarly, in neurology, miRNAs are being investigated as biomarkers for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions. In addition to diagnostics, miRNA assays are gaining traction in therapeutics, with numerous clinical trials exploring their use in targeted treatments. The integration of miRNA sequencing in prenatal screening, infectious disease diagnostics, and immune response monitoring further demonstrates its versatility. The increasing prevalence of chronic diseases and the global focus on early detection and precision medicine are expected to sustain the demand for miRNA sequencing and assays in the healthcare sector.

What Is Driving Growth in the miRNA Sequencing and Assays Market?

The growth in the miRNA sequencing and assays market is driven by several factors that underscore its pivotal role in advancing biomedical research and healthcare. The rising prevalence of cancer and chronic diseases has significantly increased the demand for miRNA-based diagnostics and therapeutics. Advancements in NGS technologies have made miRNA sequencing more accurate, cost-effective, and widely accessible, further fueling market adoption. The growing focus on personalized medicine and the increasing integration of miRNA profiling in drug discovery pipelines are also key contributors. Moreover, the expanding application of miRNAs in non-invasive liquid biopsies and their role in understanding disease mechanisms have boosted their relevance in modern medicine. Together, these drivers are propelling the miRNA sequencing and assays market toward robust growth, reshaping the landscape of genomic research and clinical practice.

SCOPE OF STUDY:

The report analyzes the miRNA Sequencing and Assays market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product & Service (miRNA Sequencing & Assay Products, miRNA Sequencing & Assay Services); Technology (Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology, Single Molecule Real-time (SMRT) Sequencing Technology); Application (Cancer Application, Polyglutamine Diseases Application, Autoimmune Diseases Application, Schizophrenia Application, Other Applications); End-Use (Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 27 Featured) -

• Abcam Plc
• HTG Molecular Diagnostics, Inc.
• Illumina, Inc.
• Lexogen
• Meridian Bioscience, Inc.
• New England Biolabs, Inc.
• Norgen Biotek Corp.
• QIAGEN NV
• System Biosciences, LLC
• Takara Bio Inc

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Economic Frontiers: Trends, Trials & Transformations
  • miRNA Sequencing and Assays - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advancements in Next-Generation Sequencing Technologies Drive miRNA Analysis Growth
  • Rising Research Activities in Cancer and Genetic Disorders Propel miRNA Sequencing Demand
  • Increasing Use of miRNA Sequencing in Biomarker Discovery Drives Market Expansion
  • Growth in Personalized Medicine Fuels Demand for miRNA Assays
  • Role of miRNA in Early Diagnosis of Diseases Boosts Market Adoption
  • Rising Applications of miRNA Sequencing in Drug Development Drive Innovation
  • Emergence of Cost-Effective miRNA Sequencing Platforms Expands Accessibility
  • Integration of AI in miRNA Analysis Enhances Research Efficiency
  • Demand for High-Throughput Screening Technologies Propels miRNA Sequencing Market
  • Rising Focus on Non-Invasive Diagnostic Techniques Drives Adoption of miRNA Assays
  • Government and Private Funding for Genomic Research Fuels Market Growth
  • Expansion of miRNA Applications in Neurological and Cardiovascular Disorders Propels Demand
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World miRNA Sequencing and Assays Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for miRNA Sequencing and Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for miRNA Sequencing and Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for miRNA Sequencing & Assay Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for miRNA Sequencing & Assay Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for miRNA Sequencing & Assay Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for miRNA Sequencing & Assay Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for miRNA Sequencing & Assay Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for miRNA Sequencing & Assay Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Autoimmune Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Autoimmune Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Autoimmune Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Schizophrenia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Schizophrenia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Schizophrenia Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Polyglutamine Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Polyglutamine Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Polyglutamine Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Research & Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Sequencing by Synthesis Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Sequencing by Synthesis Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Sequencing by Synthesis Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Nanopore Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Nanopore Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Nanopore Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Sanger Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Sanger Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Sanger Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Single Molecule Real-time (SMRT) Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Single Molecule Real-time (SMRT) Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Single Molecule Real-time (SMRT) Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 62: Canada Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• JAPAN
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 74: Japan Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• CHINA
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 86: China Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• EUROPE
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 98: Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for miRNA Sequencing and Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for miRNA Sequencing and Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• FRANCE
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 113: France Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• GERMANY
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 125: Germany Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 137: Italy Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 149: UK Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 161: Spain Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 173: Russia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for miRNA Sequencing and Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• AUSTRALIA
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 212: Australia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• INDIA
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 224: India Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for miRNA Sequencing and Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for miRNA Sequencing and Assays by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for miRNA Sequencing and Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for miRNA Sequencing and Assays by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 338: Iran Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 350: Israel Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 374: UAE Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030
• AFRICA

miRNA Sequencing and Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)

• TABLE 398: Africa Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
• TABLE 399: Africa Historic Review for miRNA Sequencing and Assays by Product & Service - miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
• TABLE 400: Africa 15-Year Perspective for miRNA Sequencing and Assays by Product & Service - Percentage Breakdown of Value Sales for miRNA Sequencing & Assay Products and miRNA Sequencing & Assay Services for the Years 2015, 2025 & 2030
• TABLE 401: Africa Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
• TABLE 402: Africa Historic Review for miRNA Sequencing and Assays by Application - Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
• TABLE 403: Africa 15-Year Perspective for miRNA Sequencing and Assays by Application - Percentage Breakdown of Value Sales for Autoimmune Diseases Application, Schizophrenia Application, Other Applications, Cancer Application and Polyglutamine Diseases Application for the Years 2015, 2025 & 2030
• TABLE 404: Africa Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
• TABLE 405: Africa Historic Review for miRNA Sequencing and Assays by End-Use - Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
• TABLE 406: Africa 15-Year Perspective for miRNA Sequencing and Assays by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• TABLE 407: Africa Recent Past, Current & Future Analysis for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
• TABLE 408: Africa Historic Review for miRNA Sequencing and Assays by Technology - Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
• TABLE 409: Africa 15-Year Perspective for miRNA Sequencing and Assays by Technology - Percentage Breakdown of Value Sales for Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology and Single Molecule Real-time (SMRT) Sequencing Technology for the Years 2015, 2025 & 2030

IV. COMPETITION